{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:01:39Z","timestamp":1792555299652,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Membranous nephropathy (MN) associated with phospholipase A2 receptor (PLA2R) antibodies is the most common cause of nephrotic syndrome in non-diabetic adult patients. This study investigated the relationship between clinical phenotypes and renal outcomes in this population, emphasizing the potential for phenotype-based treatment stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multi-center cohort study of PLA2R-positive MN. Unsupervised cluster analysis grouped patients based on clinicopathological characteristics. Primary outcomes included complete or partial remission within 2 years of biopsy and end-stage kidney disease (ESKD) or death during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 178 patients, three distinct clusters emerged (n\u00a0=\u00a089, 70, and 19). Within 2 years of biopsy, 102 patients (57%) achieved complete or partial remission. Cluster 1, characterized by the mildest disease markers, including the lowest body mass index, serum anti-PLA2R titer, serum creatinine, proteinuria, and triglycerides, had the highest remission rate of 72%, compared with 50% in cluster 2 and 54% in cluster 3. Cluster 2 had significantly lower remission compared to cluster 1 (HR 0.64, 95% CI 0.42\u20130.96, P\u00a0=\u00a0.03); results were similar in cluster 3, albeit not statistically significant (HR 0.50, 95% CI 0.23\u20131.09, P\u00a0=\u00a0.08). Elevated anti-PLA2R levels (&amp;gt;100\u00a0U\/ml) and proteinuria (&amp;gt;8\u00a0g\/24-hour) predicted reduced remission (HR 0.56, 95% CI 0.36\u20130.88, P\u00a0=\u00a0.01; HR 0.43, 95% CI 0.26\u20130.73, P\u00a0=\u00a0.002, respectively), while high high-density lipoprotein levels were protective (HR 1.01, 95% CI 1.00\u20131.02, P\u00a0=\u00a0.048). Overall, 21 patients (12%) developed ESKD or died. ESKD-free survival differed significantly across clusters (log-rank test P\u00a0=\u00a0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Unsupervised clustering identified distinct clinical phenotypes in PLA2R-positive MN, each associated with different renal prognoses. Phenotype-based risk stratification could enhance treatment precision, improve patient outcomes, and potentially reduce treatment-related adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf107","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:56:30Z","timestamp":1750233390000},"page":"2309-2318","source":"Crossref","is-referenced-by-count":5,"title":["Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-9740","authenticated-orcid":false,"given":"Jing","family":"Miao","sequence":"first","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaleh","family":"Zand","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Quantitative Health Sciences, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[{"name":"Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus CSUR Enfermedad Glomerular Compleja, Nephrology and Transplantation Research Group, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat M","family":"D\u00edaz Encarnaci\u00f3n","sequence":"additional","affiliation":[{"name":"Universitat Autonoma de Barcelona CSUR: Spain Reference Center for Complex Glomerular Diseases, ERKnet: European Reference Center for Rare Kidney Diseases. Fundaci\u00f3 Puigvert Department of Nephrology, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8476","authenticated-orcid":false,"given":"Luis F","family":"Quintana","sequence":"additional","affiliation":[{"name":"CSUR Enfermedad Glomerular Compleja, Servicio de Nefrolog\u00eda y Trasplante Renal, Hospital Cl\u00ednic de Barcelona, Universtat de Barcelona, IDIBAPS , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Bomback","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians & Surgeons, Columbia University Department of Medicine, Division of Nephrology, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wooden","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians & Surgeons, Columbia University Department of Medicine, Division of Nephrology, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-0948","authenticated-orcid":false,"given":"Shane A","family":"Bobart","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital Department of Nephrology, Hypertension and Transplantation, , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nephrology and Hypertension, Department of Medicine, , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025112604021714900_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u2018antigens\u2019 in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib3","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112604021714900_bib4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2025112604021714900_bib6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"2025112604021714900_bib7","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","article-title":"Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan","volume":"65","author":"Shiiki","year":"2004","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"2025112604021714900_bib9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/ndt\/gfm919","article-title":"The impact of sex in primary glomerulonephritis","volume":"23","author":"Cattran","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025112604021714900_bib11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/IJNRD.S149029","article-title":"The clinicopathological features of patients with membranous nephropathy","volume":"11","author":"Zhu","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2025112604021714900_bib12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025112604021714900_bib13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/Exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib15","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/ki.2015.310","article-title":"Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy","volume":"88","author":"Ramachandran","year":"2015","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112604021714900_bib17","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib18","doi-asserted-by":"publisher","first-page":"e110681","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS ONE"},{"key":"2025112604021714900_bib19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/1354750X.2014.993708","article-title":"Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens","volume":"20","author":"Medrano","year":"2015","journal-title":"Biomarkers"},{"key":"2025112604021714900_bib20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"2025112604021714900_bib21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000449513","article-title":"Should we always defer treatment of kidney disease when there is extensive interstitial fibrosis on biopsy?","volume":"44","author":"Hommos","year":"2016","journal-title":"Am J Nephrol"},{"key":"2025112604021714900_bib22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ndt\/gfw443","article-title":"Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies","volume":"33","author":"Mariani","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025112604021714900_bib23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/sj.ki.5000289","article-title":"Renal pathology in idiopathic membranous nephropathy: a new perspective","volume":"69","author":"Troyanov","year":"2006","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1139\/gen-2020-0131","article-title":"Machine learning for precision medicine","volume":"64","author":"MacEachern","year":"2021","journal-title":"Genome"},{"key":"2025112604021714900_bib25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1681\/ASN.2020030239","article-title":"Subtyping CKD patients by consensus clustering: the chronic renal insufficiency cohort (CRIC) study","volume":"32","author":"Zheng","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/jcm9041107","article-title":"Promises of big data and artificial intelligence in nephrology and transplantation","volume":"9","author":"Thongprayoon","year":"2020","journal-title":"J Clin Med"},{"key":"2025112604021714900_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1023949509487","article-title":"Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data","volume":"52","author":"Monti","year":"2003","journal-title":"Machine Learning"},{"key":"2025112604021714900_bib28","article-title":"UMAP: uniform manifold approximation and projection for dimension reduction","author":"McInnes","year":"2020"},{"key":"2025112604021714900_bib29","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.ekir.2023.05.019","article-title":"PLA2R Antibody does not outperform conventional clinical markers in predicting outcomes in membranous nephropathy","volume":"8","author":"Ragy","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025112604021714900_bib30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12882-022-02914-4","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients","volume":"23","author":"Wang","year":"2022","journal-title":"BMC Nephrol"},{"key":"2025112604021714900_bib31","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"2025112604021714900_bib32","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3390\/jcm10122624","article-title":"Clinical phenotypes and predictors of remission in primary membranous nephropathy","volume":"10","author":"Jurubita","year":"2021","journal-title":"J Clin Med"},{"key":"2025112604021714900_bib33","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1681\/ASN.2015020181","article-title":"Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase A2 receptor autoantibodies","volume":"26","author":"Brenchley","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000529415","article-title":"Phospholipase A2 receptor antibodies and clinical prognosis in patients with idiopathic membranous nephropathy: an updated systematic review and meta-analysis","volume":"48","author":"Zhang","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"2025112604021714900_bib35","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025112604021714900_bib36","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery","volume":"96","author":"van de Logt","year":"2019","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112604021714900_bib38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000182232","article-title":"Membranous nephropathy: its relative benignity in women","volume":"29","author":"Hopper","year":"1981","journal-title":"Nephron"},{"key":"2025112604021714900_bib39","doi-asserted-by":"publisher","first-page":"e007387","DOI":"10.1161\/JAHA.117.007387","article-title":"Relationship of high-density lipoprotein cholesterol with renal function in patients treated with Atorvastatin","volume":"7","author":"Ong","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025112604021714900_bib40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1046\/j.1523-1755.2001.00041.x","article-title":"Protein kinase CK2 mediates TGF-beta1-stimulated type IV collagen gene transcription and its reversal by estradiol","volume":"60","author":"Zdunek","year":"2001","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib41","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1161\/01.CIR.97.22.2197","article-title":"Estrogen modulates AT1 receptor gene expression in vitro and in vivo","volume":"97","author":"Nickenig","year":"1998","journal-title":"Circulation"},{"key":"2025112604021714900_bib42","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.genm.2008.03.002","article-title":"Gender and human chronic renal disease","volume":"5 Suppl A","author":"Silbiger","year":"2008","journal-title":"Gend Med"},{"key":"2025112604021714900_bib43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1523-1755.1999.00260.x","article-title":"Impact of gender on the renal response to angiotensin II","volume":"55","author":"Miller","year":"1999","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000049033","article-title":"Effects of sex on renal structure","volume":"90","author":"Neugarten","year":"2002","journal-title":"Nephron"},{"key":"2025112604021714900_bib45","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/ndt\/13.6.1430","article-title":"Differences between women and men with chronic renal disease","volume":"13","author":"Coggins","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"2025112604021714900_bib46","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/ijms21020601","article-title":"The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease","volume":"21","author":"Rysz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025112604021714900_bib47","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with Obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025112604021714900_bib48","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"key":"2025112604021714900_bib49","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/ndt\/gfad135","article-title":"Plasma cell-directed therapy for rituximab-refractory PLA2R+ membranous nephropathy","volume":"38","author":"Salhi","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025112604021714900_bib50","doi-asserted-by":"publisher","first-page":"sfae129","DOI":"10.1093\/ckj\/sfae129","article-title":"Ten tips on immunosuppression in primary membranous nephropathy","volume":"17","author":"Trujillo","year":"2024","journal-title":"Clin Kidney J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf107\/63522259\/gfaf107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2309\/63522259\/gfaf107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2309\/63522259\/gfaf107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:02:22Z","timestamp":1764147742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/12\/2309\/8168477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf107","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,18]]}}}